Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
295 GBX | 0.00% | -5.75% | -16.31% |
Apr. 02 | MaxCyte inks deal with Be Bio; Orcadian firms farmout | AN |
Apr. 02 | MaxCyte, Inc. Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.31% | 385M | |
+7.71% | 218B | |
+6.25% | 182B | |
+10.60% | 132B | |
+26.73% | 108B | |
-0.46% | 62.51B | |
+15.42% | 52.98B | |
-1.89% | 47.59B | |
-1.91% | 39.96B | |
+11.16% | 39.22B |
- Stock Market
- Equities
- MXCT Stock
- News MaxCyte, Inc.
- MaxCyte : Grants Sana Biotechnology Commercial Rights On Cell-Engineering Tech